Order Article Reprints

Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, et al. Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan. Cancers. 2021; 13(14):3554. https://doi.org/10.3390/cancers13143554

Uchimoto, Taizo, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Yusuke Yano, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga, and et al. 2021. "Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan" Cancers 13, no. 14: 3554. https://doi.org/10.3390/cancers13143554

Uchimoto, T., Komura, K., Fukuokaya, W., Kimura, T., Takahashi, K., Yano, Y., Nishimura, K., Nakamori, K., Fujiwara, Y., Matsunaga, T., Tsutsumi, T., Tsujino, T., Maenosono, R., Yoshikawa, Y., Taniguchi, K., Tanaka, T., Uehara, H., Hirano, H., Nomi, H., ... Azuma, H. (2021). Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan. Cancers, 13(14), 3554. https://doi.org/10.3390/cancers13143554